Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordec Group grew profitably and continued to invest in the development of its business during 2023.

Year 2023 highlights · Strong performance in the execution of Nordec’s strategy continued. Our teams were strengthened, particularly within sales and design management, and modernization investments in factories continued. Within sustainability, low-carbon solutions were developed further during the year. · Nordec Group continued its strong financial performance in 2023; revenue grew by 6,2 % to EUR 329,2 million. Adjusted EBITDA improved to EUR 27,0 million, amounting to 8,2 % of revenue. · Operating cash flow was clearly positive, and the balance sheet strengthened.Nordec Group

Notice to the Annual General Meeting of Toivo Group Plc

Toivo Group Plc company release 19 March 2024 at 09:00 a.m. EET Notice is given to the shareholders of Toivo Group Plc (the “Company”) to participate in the Annual General Meeting to be held on Thursday 11 April 2024 at 10:00 a.m. at the Leppävaara campus of Laurea University of Applied Sciences at Vanha Maantie 9, 02650 Espoo, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at the venue at 9:30 a.m. EET. A. Matters on the agenda of the Annual General Meeting The following matters will be considered at the

Transaction in Own Shares

    19 March 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |18/03/2024|+-------------------------------------------------------------

Electrolux Group publishes restated figures for the new business area structure

As previously announced, Electrolux Group has reorganized into three regional business areas as of 1 January 2024. To enable comparisons with future financial reporting, restated historical figures for the combined business area Europe, Asia-Pacific, Middle East and Africa, per quarter and full year for 2022 and 2023, are provided.As announced on October 27, 2023, the two business areas Europe and Asia-Pacific, Middle East and Africa have been combined into one business area. The other two business areas, North America and Latin America, remain. The new structure will leverage the Group’s

Peab builds assisted living in Åmål

Peab has been commissioned to build a new assisted living in Åmål. The customer is Åmål Municipality and the contract is worth SEK 220 million.The project entails building 50 new apartments for people with special needs. The building will also contain a production kitchen with reserve power and water. The gross area amounts to 5,600 m2 and large parts of the bearing frame will consist of cross-laminated timber (CLT). “There is a great need for assisted living in the municipality and we’re pleased and proud to finally get started on this fantastic project,” says Björn Wennerström, Head of

Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease

Stockholm, Sweden, March 19, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer's disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18.Professor Lannfelt received the award for his groundbreaking research, which has played a significant role in the scientific progress in the field over decades, leading to the development of lecanemab, a disease-modifying treatment for early Alzheimer's disease approved in the U.S., Japan

Commencement of Further Share Buyback Programme

19 March 2024   PHSC PLC (“PHSC” or the “Company”)   Commencement of Further Share Buyback Programme   PHSC (AIM: PHSC), a leading provider of health, safety, hygiene and environmental consultancy services and security solutions to the public and private sectors, is pleased to announce the commencement of a further share buyback programme in respect of ordinary shares of 10p each in the capital of the Company (“Ordinary Shares”) up to a maximum of 1,777,053 Ordinary Shares or such number of Ordinary Shares as may be acquired for a gross amount of £200,000, whichever is

Implantica wins another RefluxStop™ public tender in Europe, this time in Spain with Hospital Universitario de Getafe

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first-in-the-country public tender win for RefluxStop™ at Hospital Universitario de Getafe, a public hospital in Madrid, Spain.Dr. Juan Carlos Ruiz de Adana and Dr. Alberto Hernández Matías successfully performed ten RefluxStop™ procedures at Hospital Universitario de Getafe, over the last year. In line with the successful outcomes of these cases, the hospital has secured a first-of-its-kind RefluxStop™ public tender in Spain. This is a crucial milestone not only for the

Outlook 2024

Company announcement from SGL Group ApS 19 March 2024 Company announcement no. 7 For 2024 we expect to see a positive development in activity levels for the airfreight market. To some extent, airfreight rates are expected to remain elevated above pre-pandemic levels. For ocean freight we expect that gross supply will continue to outweigh demand, but somewhat balanced considering the infrastructural and geo-political impacting factors. SGL Group will continue pursuing a diversified business model with high focus on a balanced volume portfolio across transport mode and across trade-

SGL Group ApS considers issuance of new senior secured bonds, potential buy-backs and a related voluntary partial redemptions of its outstanding bonds

Company announcement from SGL Group ApS 19 March 2024 Company announcement no. 8 SGL Group ApS (formerly Skill BidCo ApS (the "Company") announces today (i) that it has mandated Pareto Securities AB as Sole Global Coordinator and Sole Bookrunner to consider an issuance of new senior secured bonds (the "Bond Issue") and (ii) an invitation to holders of its outstanding EUR 750,000,000 Senior Secured Callable Floating Rate Bonds (ISIN: NO0012826033) (the "Existing Bonds") to tender their Existing Bonds (the "Buy-Back"). Holders of Existing Bonds participating in the Bond Issue will be

Eevia Health Plc finalizes a key development project and receives grant payment for c. 2,747 KSEK (243 KEUR)

Eevia Health ("Eevia" or "The Company") has finalized a development project for the documentation of bioactivity on its products, which was co-funded by Business Finland. Eevia executed the project in 2023 and filed the final report in February 2024. The report is now approved. Last week, Eevia received the grant payment of c. 2,747 kSEK (243 kEUR) from Business Finland.A central activity in the project was a broad in vitro screening of Eevia's top extracts on the Eurofins BioMAP phenotyping platform. The successful execution of the study provided Eevia with troves of insightful new

Health economic study shows positive outcome using Integrum’s OPRA[TM] Implant System over socket prostheses in transfemoral amputees

Mölndal, Sweden – March 19, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that a team of independent researchers, from six prestigious academic and clinical institutions in the US, have published a health economic article analyzing potential effects on societal cost-control and quality-of-life when utilizing osseointegrated transfemoral prostheses compared to traditional socket prostheses. The study’s meta-analyses show that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times

Nightingale Health’s technology used to analyze Uganda’s General Population Cohort (GPC)

Press release, 19 March 2024 at 8:00 a.m. (EET) Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, has entered into an agreement in which it will analyze blood samples from Uganda’s General Population Cohort (GPC). The GPC is a population-based study of approximately 22,000 individuals residing in southwestern Uganda. The study represents ten ethnolinguistic groupings and is the first from the region to be analyzed by Nightingale Health’s technology. It has been widely suggested that ethnic differences play a role in the

Pihlajalinna has published the 2023 Annual Report

Pihlajalinna Plc                 Stock Exchange Release                 19 March 2024 at 8:00 a.m. Pihlajalinna has published the 2023 Annual ReportPihlajalinna’s Annual Report for 2023 has been published on the Company’s website at the address investors.pihlajalinna.fi . The Annual Report 2023 consists of five parts: The Year 2023, Sustainability, Remuneration, Corporate Governance and Finance. The section The Year 2023 provides information on Pihlajalinna’s business operations and strategy and the key events that took place during the

Impero A/S: Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

Company Announcement No. 5-2024 Copenhagen, 18 March 2024 Impero A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in Impero A/S made by persons discharging managerial responsibilities in Impero and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associateda) Name Rikke Stampe Skov2. Reason for the notificationa) Position/status CEOb) Initial

Capital increase in Impero A/S in connection with exercise of warrants

Company Announcement No. 4-2024 Copenhagen, 18 March 2024 Impero A/S announces today that Impero A/S’ share capital is increased by nominally DKK 93,000 as a result of exercise of warrants issued under the company’s warrant program. Among the participants in the warrant exercise are a number of employees in Impero A/S, CEO Rikke Stampe Skov, Vice Chair Sten T. Davidsen, and Board Member Carsten Gerner. As of 18 March 2024, instructions have been received to exercise 930,000 warrants. 525,000 shares are subscribed in cash at a price of DKK 2.40 per share with a nominal value of 0.10

PDMR Transfer of Shareholding

Kasei Digital Assets plc (‘Kasei’ or the ‘Company’) PDMR Transfer of ShareholdingThe Company was notified on 15 March 2024 that Bryan Coyne, a Non-Executive Director of the Company, has transferred 238,095 ordinary shares in the Company to a self-invested personal pension (SIPP) account for £0.105 per ordinary share consideration. Bryan Coyne remains the beneficial holder of these shares. This notification is made in accordance with the requirements of the Market Abuse Regulation. NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES OR

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 18 March 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 18 March 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)Number of

The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW. The Board of Directors in Diamyd Medical AB (publ)

Repurchases of shares in Hoist Finance during week 11, 2024

During the period 11 March 2024 – 15 March 2024 Hoist Finance AB (publ) (LEI code: 549300NPK3FB2BEL4D08) (”Hoist Finance”) has repurchased in total 205,000 own shares (ISIN: SE0006887063), as part of the repurchase programme initiated by the Board of Directors. The repurchases form part of the repurchase programme of a maximum of 10 percent of the total number of shares in the company for a total amount of not more than SEK 100,000,000 that Hoist Finance announced on 6 February 2024. The repurchase programme runs during the period from and including 8 February 2024 until the Annual

Buy-back of shares in Arise during week 11, 2024

During the period between 11 March and 15 March 2024 Arise AB (publ) (LEI code 549300FOT7EE85QYB655) (“Arise”) repurchased, in total, 86,464 own shares (ISIN code SE0002095604) under the share repurchase program initiated by the Board of Directors to deliver shareholder value and to optimize the capital structure of the company. The share buy-backs form a part of the share repurchase program of a maximum amount of SEK 100 million, which Arise announced on 14 November 2023. The share repurchase program, which runs from 16 November 2023 until the date of Arise's Annual General Meeting in

There are no items matching the current filter
There are no more items matching the current filter
Back to top